Botfet / Company detail

AGIO

rejected

Agios Pharmaceuticals, Inc.

biotech

Moat scoreNot available: not scored quality failout of 100
Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context
Roic-38.2%
Gross Margin78.7%
Revenue Cagr56.0%
Fcf Conversion91.4%
Fcf Yield-16.9%
Interest Coverage0.0x
Market Cap B$2.2B
PeNot available: not applicable loss making
Quality PassFail
Founder LedNo
Thesis AlignedYes
Moat QuantNot available: not scored quality fail

Why it may endure

Moat breakdown

Quant: Not available: not scored quality fail · Curator: Not available: not scored quality fail
Market Share StabilityNot available: not scored quality fail
Network EffectsNot available: not scored quality fail
Pricing PowerNot available: not scored quality fail
Regulatory MoatNot available: not scored quality fail
Switching CostsNot available: not scored quality fail
ConvictionNot available: not scored quality fail
LeadershipNot available: not scored quality fail
VisionNot available: not scored quality fail
← Back to the full screener